脓毒症性凝血病诊疗中国专家共识2024版_宋景春

Med]Chin PLA,Vol.49,No.11,November 28,2024指南与共识脓毒症性凝血病诊疗中国专家共识(2024版)宋景春”，丁仁或2，吕奔3，梅恒4，王岗5，张伟6，周静7，郭军8，中国医药教育协会血栓与止血危重病专业委员会，全军重症医学专业委员会解放军联勒保障部队第908医院重症医学科，江西南昌330002：2中国医科大学附属第一医院重症医学科，辽宁沈阳110001；3中南大学湘雅二医院血液科，湖南长沙410011；4华中科技大学同济医学院附属协和医院血液科，湖北武汉430030；5西安交通大学第二附属医院重症医学科，陕西西安710004；“解放军联勒保障部队第900医院急诊科，福建福州350002；7四川大学华西医院实验医学科，四川成都610041；四川大学华西医院重症医学科，四川成都610041[中图分类号]R459.7[文献标志码]A[D0]10.11855/1issn.0577-7402.11892024.0918[声别本文所有作者声明无利益冲突[引用本文]宋景春，丁仁或，昌奔，等.脓毒症性凝血病诊疗中国专家共识(2024版)门.解放军医学杂志，2024,49(11)：1221-1236[收稿日期]2024-08-02[录用日期]2024-09-08[上线日期]2024-09-18[摘要]脓毒症性凝血病(SC)是脓毒症导致的血管内皮损伤和凝血紊乱，是导致脓毒症患者死亡的重要因素。对SC实现早期诊断和治疗有望改善患者的预后。2019年国际血栓止血学会STH)颁布了首部SIC诊疗指南，但我国尚无相关规范。因此，中国医药教育协会血栓与止血危重病专业委员会和全军重症医学专业委员会共同编写了《脓毒症性凝血病诊疗中国专家共识(2024版)》。该共识包括发病机制、分型、实验室评估、诊断和治疗等5个部分，共14条推荐意见：以便指导相应的临床工作。[关键词]脓毒症；凝血病；免疫血栓；血栓炎症；表型；抗凝Chinese expert consensus on the diagnosis and treatment of sepsis-induced coagulopathy(2024 edition)Song Jing-Chun",Ding Ren-Yu',Lyu Ben',Mei Heng,Wang Gang,Zhang Wei,Zhou Jing,Guo Jun,Chinese Society ofThrombosis,Hemostasis and Critical Care,Chinese Medicine Education Assocation,and Chinese People's Liberation Army ProfessionalCommittee of Critical Care MedicineDepartment of Critical CareMedicine,the9th Hospital of the PLA Joint Logistic Support Force,Nanchang Jiangxi 330002,China-Department of Critical Care Medicine,the First Affiliated Hospital of Chinese Medical University,Shenyang,Liaoning 110001,ChinaDepartment of Hematology,the Second Xiangya Hospital,Central South University,Changsha,Hunan 410011,ChinaDepartment of Hematology,Union Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,ChinaDepartment of Critical Care Medicine,the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an Shaanxi710004,ChinaDepartment of Emergency,the 900th Hospital ofthe PLAJoint Logistic Support Force,Fuzhou,Fujian 350002,ChinaDepartment of Laboratory Medicine,Department of Critical Care Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,ChinaCorresponding author,E-mail:songjingchun@126.com[Abstract]Sepsis-induced coagulopathy (SIC),a critical and potentially lethal condition arising from sepsis,results inendothelial damage and significant coagulation dysregulation,making it a major factor contributing to mortality among sepsispatients.Early diagnosis and treatment of SIC are expected to improve the prognosis of sepsis patients.In 2019,the InternationalSociety on Thrombosis and Hemostasis(ISTH)issued the first guidelines for the diagnosis and treatment of SIC,but there are nocorresponding protocols in China.Therefore,Chinese Society of Thrombosis,Hemostasis and Critical Care,Chinese MedicineEducation Association,and Chinese People's Liberation Army Professional Committee of Critical Care Medicine jointly formulated[作者简介]宋景春，医学博土，主任医师，主要从事血栓与止血危重病方面的研究[通信作]宋景春，E-mail:0 gingchun@126.com中国知网https://www.cnki.net